Apollomics Stock
Apollomics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Hung-Wen Chen
- Employees
- 14
- Market cap
- $62 M
- IPO
- 26/11/2021
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address…
Apollomics stock: price history
1D
+0.5%
1W
-1.9%
1M
-4.6%
6M
+51.8%
YTD
+12.8%
1Y
-34.0%
2Y
+68.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
01/04/2027 (in 166 days)
Volatility around earnings
~38% stronger price swings than usual
Ask the agents about Apollomics
Analyst assessment of Apollomics
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 08/05/2024
Apollomics stock metrics
P/E
-2.79
P/B
-2.79
EV/EBITDA
-6.29
RETURN ON EQUITY
-50.1%
NET MARGIN
0.0%
DEBT/EQUITY
-0.2
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
56.6%
FLOAT SHARES
1,648,412
AVG. DAILY VOLUME (30D)
8,668
Insider transactions (SEC)
Chen Hung-Wen
LIN PETER KUAN-HOW
LIN PETER KUAN-HOW
CHEN HONG-JUNG
Chen Yi-Kuei
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Apollomics stock
What does Apollomics do?
Apollomics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Hung-Wen Chen, the company employs around 14 people.
The IPO was on 26/11/2021; the stock trades on NASDAQ under the ticker APLM.
What do analysts say about Apollomics stock?
2 analysts rate the stock, the consensus is Buy (as of 08/05/2024).
This is an external assessment, not a statement by Market Jury.
When does Apollomics report next?
The next earnings date is 01/04/2027.
Around past earnings, price swings were roughly 38% stronger than usual.
Does Apollomics pay a dividend?
No, Apollomics currently does not pay a dividend.
Which stocks are comparable to Apollomics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Apollomics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Apollomics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.